SQLite Web: event_store.db

Update row sig_8ea9ca1950e3 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-041507.txt","as_of":"2026-04-10T03:04:31.796915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-041507.txt","company":"Theriva Biologics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-041507.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_791005bff1b3f624","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-041507.txt","content_type":"text/plain","enriched_at":"2026-04-10T03:23:53.523214+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-041507.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-041507.txt","source_event_id":"evt_90fb7ff51740","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"a96c0b5f7e668dee","kind":"sec_filing","published_at":"20260409","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-09","2026-04-10","2026-03-16","2025-10-16"],"entities":[{"asset_class":"equity","name":"Theriva Biologics, Inc.","relevance":"high","symbol":"TOVX","type":"issuer"},{"asset_class":"other","name":"SEC","relevance":"medium","symbol":"","type":"regulator"},{"asset_class":"other","name":"Special Meeting of Stockholders","relevance":"high","symbol":"","type":"corporate_action"},{"asset_class":"other","name":"Inducement Agreement","relevance":"high","symbol":"","type":"contract"}],"event_type":"listing","information_gaps":["The filing\u2019s SEC Item number(s) beyond the provided text (it states Item 8.01. Other Events) are not further detailed in the excerpt.","No details are provided on the closing date of the transactions contemplated by the Inducement Agreement, so the actual deadline for the initial 60-day meeting cannot be determined from the text.","No information is provided on whether investors waived the requirement to continue calling meetings after the quorum failure.","No financial guidance or financial statement impact is included in the provided text."],"key_facts":["Theriva Biologics filed a Form 8-K with the SEC reporting events dated April 9, 2026.","On April 9, 2026, the company called to order a Special Meeting of Stockholders.","At the time of calling the Special Meeting, there were not present or represented by proxy a sufficient number of shares to constitute a quorum.","Because quorum was not achieved, the company was not able to convene the Special Meeting.","The company determined to call a new meeting of stockholders to seek approval of the warrant exercise proposal and adjournment proposal set forth in a definitive proxy statement filed March 16, 2026.","The company intends to file with the SEC and mail proxy materials that include information regarding the date and time of the new meeting, as required.","Under a warrant inducement agreement dated October 16, 2025, the company agreed to use reasonable best efforts to call a stockholder meeting within 60 days following the closing of the transactions contemplated by the agreement to seek approval of issuance of up to an aggregate of 16,184,560 shares upon exercise of certain common stock purchase warrants (\"New Warrants\").","If stockholder approval is not obtained and unless waived by the investors, the company will be required under the Inducement Agreement to continue to call an additional meeting every 60 days thereafter until stockholder approval is obtained or the New Warrants are no longer outstanding."],"numeric_claims":[{"label":"shares for issuance upon warrant exercise (aggregate)","value":"16,184,560"},{"label":"meeting call frequency after failed meeting (if not waived)","value":"every 60 days"},{"label":"agreement meeting timing after closing (reasonable best efforts)","value":"within 60 days following closing"},{"label":"definitive proxy statement filing date","value":"March 16, 2026"},{"label":"inducement agreement date","value":"October 16, 2025"},{"label":"special meeting date","value":"April 9, 2026"}],"primary_claim":"On April 9, 2026, Theriva Biologics was unable to convene its special meeting because a sufficient number of shares were not present or represented by proxy to constitute a quorum.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Theriva Biologics, Inc. filed a Form 8-K on April 9, 2026 stating that its April 9, 2026 special stockholders\u2019 meeting could not be convened due to lack of quorum. The company intends to call a new meeting to seek stockholder approval related to warrant exercise and adjournment proposals described in its March 16, 2026 definitive proxy statement.","topics":["Form 8-K","special meeting","quorum failure","stockholder approval","warrant exercise proposal","adjournment proposal","proxy statement","warrant inducement agreement","New Warrants","stockholder approval cadence"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Theriva Biologics, Inc. \u00b7 Filed 20260409","ticker":"TOVX","tickers":["TOVX"],"title":"TOVX filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-041507.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel